CBAY News and Press, CymaBay Therapeutics Inc. From 11/05/20

CymaBay announces trial design for RESPONSE , a global phase 3 registration stud y for seladelpar in primary biliary cholangitis (PBC) Results from the ENHANCE phase 3 study evaluating seladelpar for PBC to be featured in an oral ...

NEWARK, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced it will provide its proprietary investigational ...

NEWARK, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced that a late-breaking presentation h...

Gainers: [[TRUE]] +6.2%. [[AR]] +5%. [[BCC]] +4.8%.[[GTHX]] +4.5%. [[SHLX]] +2.7%.Losers: [[ORTX]] -14.6%. [[UUU]] -6.8%. [[MDCA]] -6%. [[NRT]] -4.2%. [[CBAY]] -3%. For further details see: AR, SHLX, CBAY and ORTX among after-hours movers

NEWARK, Calif., Oct. 30, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live aud...

Gainers: [[DSS]] +26.5%. [[PRVB]] +8.4%. [[GRTS]] +4.7%. [[LILA]] +3.4%. [[NVTA]] +3.1%.Losers: [[ATHM]] -6.9%. [[MRIN]] -5.2%. [[CRMD]] -3.8%. [[QLYS]] -3.3%. [[CBAY]] -2.3%. For further details see: DSS, PRVB, ATHM and QLYS among after-hours movers

United Micro Corporation (UMC), Wipro Limited (WIT), CimbaBay Therapeutics (CBAY), Pacific Ethanol (PEIX) and Surface Oncology (SURF) are five stocks, under $10, that are rated "Strong Buys" and should continue to see gains in 2021. Plenty of tech stocks and other growth-oriented stocks ...

NEWARK, Calif., Oct. 01, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced that data from a Phase 2 study of s...

Milestone Pharmaceuticals Strengthens Board of Directors with Two New Appointments Canada NewsWire MONTREAL and CHARLOTTE, N.C., Sept. 22, 2020 MONTREAL and CHARLOTTE, N.C., Sept. 22, 2020 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST)...

Quick Take Metacrine ( MTCR ) intends to raise $85 million from the sale of its common stock in an IPO, according to an amended registration statement . The company is developing treatment candidates for NASH conditions. MTCR is entering Phase 2 trials and will have significant capital ...